Search clinical trials for: Sintilimab ，bevcizumab/cetuximab，XELOX

Total 174 results

Xijing Hospital

Recruiting

A Small-sample, Real-world Study of Sintilimab Plus Bevacizumab/Cetuximab Plus XELOX Regimen for Conversion Therapy in Patients With Advanced Colorectal Cancer

Colorectal Cancer

China
Henan Cancer Hospital

Not yet recruiting

Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

Gastric Cancer

China
Sun Yat-sen University

Recruiting

Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

China
Xiaofeng Chen

Recruiting

XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)

Sintilimab, Cetuximab, Regorafenib,Combine,mCRC

China
GERCOR - Multidisciplinary Oncology Cooperative...
Hoffmann-La Roche

Active, not recruiting

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (STRATEGIC-1)

Colorectal Cancer Metastatic

Ireland, France, Israel
Second Affiliated Hospital, School of Medicine,...

Recruiting

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Colorectal Cancer Stage IV

China
Tang-Du Hospital

Recruiting

Clinical Study of Taurine Combined With Sintilimab and Chemotherapy for Treatment of Advanced Gastric Cancer

Gastric Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts

Colo-rectal Cancer

China
Harbin Medical University
Sun Yat-sen University; Fudan University; Cancer Institute and Hospital, Chinese... and other collaborators

Unknown

XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer

Colorectal Neoplasms | Chemotherapy

China
Gruppo Oncologico del Nord-Ovest

Completed

Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient (MACBETH)

Metastatic Colorectal Cancer

Italy
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.

Colorectal Cancer

Canada, Australia, New Zealand
RenJi Hospital

Active, not recruiting

Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer

Rectal Cancer Stage III

China
Emory University
Genentech, Inc.

Withdrawn

Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy

Esophageal Carcinoma
Sun Yat-sen University

Unknown

Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer

Non Small Cell Lung Cancer | Bevacizumab | Brain Metastases | Sintilimab

China
Sun Yat-sen University

Recruiting

Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial

Hepatocellular Carcinoma

China
Fudan University

Not yet recruiting

Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC

Hepatocellular Carcinoma
Hoffmann-La Roche

Withdrawn

A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab

Colorectal Cancer
Sun Yat-sen University

Recruiting

TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study (T-Double)

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Withdrawn

IBI397 or Combination Therapies in Patients With Advanced Malignancies

Advanced Malignancies

China
Tang-Du Hospital

Not yet recruiting

Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy

Rectal Cancer
Spanish Cooperative Group for the Treatment of...
Roche Pharma AG

Completed

Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) (VISNU-2)

Colorectal Cancer Metastatic

Spain
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Completed

Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

United States
Hospices Civils de Lyon

Terminated

Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases

Neoplasm Metastasis | Colorectal Cancer

France
Yonsei University

Recruiting

Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases

Metastatic Colorectal Cancer

Korea, Republic of
Grupo Hospital de Madrid

Unknown

Angiogenic Switch in Patients With Colorectal Cancer (ANGIOSWITCH)

Colorectal Cancer

Spain
University of Miami

Recruiting

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

Glioblastoma Multiforme | Anaplastic Astrocytoma | Oligodendroglioma | Diffuse Intrinsic Pontine Glioma | DIPG Brain Tumor | H3 K27M | Fibrillary Astrocytomas | Diffuse Intrinsic Brainstem Glioma

United States
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Tongji Hospital
Wuhan University; Henan Cancer Hospital; Qilu Hospital of Shandong University; Hubei... and other collaborators

Recruiting

Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma (INOVA)

Ovarian Clear Cell Carcinoma

China
Second Affiliated Hospital of Guangzhou Medical...

Active, not recruiting

TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC

Hepatocellular Carcinoma Non-resectable

China
Sun Yat-sen University

Recruiting

Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria) (BEST)

Hepatocellular Carcinoma

China
Fudan University

Recruiting

Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

Colorectal Cancer | Liver Metastases

China
Yongchang Zhang

Recruiting

Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT

Hepatocellular Carcinoma Non-resectable

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer

Liver Cancer
West China Hospital

Recruiting

Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer

Stomach Neoplasm

China
Dutch Colorectal Cancer Group
Sanofi; Roche Pharma AG; Koningin Wilhelmina Fonds; Immunicon

Completed

Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer

Colorectal Cancer

Netherlands
The University of Texas Health Science Center at...

Completed

Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer

Carcinoma, Squamous Cell of Head and Neck

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Shanghai Zhongshan Hospital

Not yet recruiting

A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
Taiwan Leader Biotech Corp.

Not yet recruiting

LEAC-102 for Advanced Colorectal Cancer

Advanced Colorectal Cancer
Huazhong University of Science and Technology

Recruiting

SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC

Metastatic Colorectal Cancer

China
Istituto Scientifico Romagnolo per lo Studio e...

Completed

Sequential Treatment Strategy for Metastatic Colorectal Cancer (ITACa)

Metastatic Colorectal Cancer

Italy
Ruijin Hospital

Recruiting

Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Lung Neoplasm Malignant

China
Zhejiang Cancer Hospital

Not yet recruiting

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Metastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRC

China
Sun Yat-sen University
Xiangya Hospital of Central South University; Nanfang Hospital of Southern... and other collaborators

Recruiting

A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)

Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma by BCLC Stage

China
Fudan University

Not yet recruiting

Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study

Metastatic Colorectal Cancer
Peking University Cancer Hospital & Institute
Zhejiang Cancer Hospital; West China Hospital; The First Affiliated Hospital... and other collaborators

Completed

Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis (PARECEC)

Metastasis | Colorectal Cancer Stage IV

China
Tianjin Medical University Cancer Institute and...

Recruiting

HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC

Hepatocellular Carcinoma

China
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC (BASKETⅡ)

Colorectal Cancer | Immunotherapy

China
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

Colorectal Carcinoma

3

Subscribe